BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
BioNTech SENASDAQ: BNTX
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income remains negative
Q2 FY2026 operating income was -€948.1M, compared with -€501.1M a year earlier. Trailing-twelve-month operating income was -€1.9B.
Context
- Operating income amounted to 22.6% of revenue in FY2025, down 25.1 pp from a year earlier.
- Operating income increased in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 11 analysts of -€1.36B (-118.5%) for the fiscal year ending Dec 2026, a slowdown from the +52.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -€948.1M-41.1% QoQ
- Last fiscal yearDec 2025
- -€623.87M+52.5% YoY
- LTMJun 2026
- -€1.9B-116.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -89.2% | +555.2% | +644.4 pp |
| 1 year | +52.5% | -118.5% | -171.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
EUR · from the income statement
- Latest · FY2025
- (623.87M) EUR
- Year-over-year change
- +52.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (623.87M) | +52.5% |
| FY2024 | 2024-12-31 | (1.31B) | -290.4% |
| FY2023 | 2023-12-31 | 690.4M | -94.5% |
| FY2022 | 2022-12-31 | 12.64B | -17.3% |
| FY2021 | 2021-12-31 | 15.28B | — |
Operating Income vs competitors
How BNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -116.6% is the 9th highest of 10, against a peer median of +38.3%.
- Operating income amounts to 71.8% of revenue for BNTX, versus a peer median of 41.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.84B USD | +89.2% | +31.4% | 31.6% | |
| LTM Jun 2026 | $1.33B USD | — | -41.6% | 32.3% | |
| LTM Sep 2026 | $192.86M USD | +87.6% | — | 21.5% | |
| LTM Mar 2026 | $30.7M USD | +307.5% | — | 42.3% | |
| LTM Mar 2026 | -$29.36M USD | +38.3% | — | 7.6% | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -€212.71M EUR | -251.5% | — | 570.3% | |
| LTM Jun 2026 | -$216.08M USD | -69.5% | — | 205.8% | |
| LTM Sep 2026 | -$230.38M USD | +44.0% | — | 60.8% | |
| LTM Sep 2026 | -$274.16M USD | -5.1% | — | 150.2% | |
| LTM Jun 2026 | -€1.9B EUR | -116.6% | — | 71.8% | |
| Peer median (excluding BNTX) | — | +38.3% | -5.1% | 41.4% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B |
| Cost of Revenue | 2.91B | 3B | 599.8M | 541.3M | 616.47M |
| Gross Profit | 16.07B | 14.32B | 3.22B | 2.21B | 2.14B |
| Gross Margin | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| Research & Development | 949.2M | 1.54B | 1.78B | 2.25B | 2.02B |
| Selling, General & Admin | 327.2M | 541.2M | 557.7M | 599M | 698.2M |
| Operating Expenses | 781.4M | 1.67B | 2.53B | 3.52B | 2.76B |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| EBITDA | 15B | 13.1B | 1.38B | (367.1M) | (628M) |
| EBITDA Margin | 79.1% | 75.7% | 36.1% | -13.3% | -22.8% |
| Operating Income | 15.28B | 12.64B | 690.4M | (1.31B) | (623.87M) |
| Operating Margin | 80.5% | 73.0% | 18.1% | -47.8% | -22.6% |
| Interest Income | 1.56M | 47.37M | 351.31M | 0 | 252.24M |
| Interest Expense | 5.63M | 15.82M | 7.76M | 13.16M | 13.64M |
| Other Income / Expenses | (237.4M) | 311.4M | 495.7M | 636.6M | (385.46M) |
| Income Before Tax | 15.05B | 12.95B | 1.19B | (677.7M) | (1.01B) |
| Pre-Tax Margin | 79.3% | 74.8% | 31.1% | -24.6% | -36.6% |
| Income Tax Expense | 4.75B | 3.52B | 255.8M | (12.4M) | 81.93M |
| Net Income | 10.29B | 9.43B | 930.3M | (665.3M) | (1.09B) |
| Net Margin | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| EPS (Basic) | 43.87 | 38.08 | 3.87 | (2.77) | (4.51) |
| EPS (Diluted) | 41.21 | 37.09 | 3.83 | (2.77) | (4.51) |
| Weighted Avg Shares | 244M | 243.3M | 240.6M | 240.4M | 241.7M |
| Weighted Avg Shares (Diluted) | 259.7M | 249.8M | 242.7M | 240.4M | 241.7M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.